HA
HAE.US Haemonetics Corporation
- Market cap
- USD 5.60B
- P/E
- 54.4x
- P/B
- 6.23x
- ROE
- 17.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is HAE.US undervalued?
Graham numberThe Graham number of Haemonetics Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Haemonetics Corporation fundamental analysis
No fundamental analysis for Haemonetics Corporation yet.
Haemonetics Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their dono…
Full company profileHaemonetics Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Haemonetics Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 886M | 904M | 968M | 988M | 870M | 993M | 1.17B | 1.31B | 1.36B | 1.33B | 1.39B |
| Gross Profit | 378M | 412M | 418M | 488M | 428M | 531M | 623M | 712M | 779M | 744M | 847M |
| Operating Income | -19.4M | 56.2M | 83.5M | 103M | 89.7M | 80.8M | 156M | 165M | 222M | 241M | 265M |
| EBITDA | 129M | 153M | 193M | 276M | 184M | 203M | 261M | 304M | 363M | 268M | 355M |
| Net Income | -26.3M | 45.6M | 55.0M | 76.5M | 79.5M | 43.4M | 115M | 118M | 168M | 97.3M | 159M |
| EPS | -0.51 | 0.85 | 1.04 | 1.48 | 1.55 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 | 3.41 |
| Balance Sheet | |||||||||||
| Total Assets | 1.24B | 1.24B | 1.27B | 1.27B | 1.82B | 1.86B | 1.93B | 2.20B | 2.45B | 2.40B | 2.41B |
| Total Liabilities | 499M | 485M | 607M | 680M | 1.09B | 1.11B | 1.12B | 1.24B | 1.63B | 1.60B | 1.51B |
| Shareholders' Equity | 740M | 752M | 668M | 587M | 732M | 749M | 818M | 960M | 821M | 796M | 898M |
| Cash & Short-term Investments | 140M | 180M | 169M | 137M | 192M | 259M | 284M | 179M | 307M | 245M | 261M |
| Total Debt | 315M | 254M | 350M | 442M | 778M | 781M | 766M | 808M | 1.22B | 1.22B | 1.12B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 160M | 220M | 159M | 158M | 109M | 172M | 273M | 182M | 182M | 293M | 361M |
| Capital Expenditure | 76.1M | 74.8M | 119M | 48.8M | 37.0M | 96.5M | 110M | 38.1M | 39.3M | 32.8M | 34.2M |
| Free Cash Flow | 83.6M | 146M | 40.3M | 109M | 71.8M | 75.8M | 163M | 144M | 142M | 260M | 327M |
| Ratios | |||||||||||
| ROE | -3.6% | 6.1% | 8.2% | 13.0% | 10.9% | 5.8% | 14.1% | 12.2% | 20.4% | 12.2% | 17.7% |
| ROA | -2.1% | 3.7% | 4.3% | 6.0% | 4.4% | 2.3% | 6.0% | 5.4% | 6.8% | 4.1% | 6.6% |
| Net Profit Margin | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% | 11.4% |
| Debt to Equity | 0.43x | 0.34x | 0.52x | 0.75x | 1.06x | 1.04x | 0.94x | 0.84x | 1.49x | 1.54x | 1.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Haemonetics Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 7.02M | 0.14 | 6.1% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 12.0M | 0.23 | 15.7% |
| 2019 | USD 13.4M | 0.25 | 24.4% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Dec 3, 2012.
Who owns Haemonetics Corporation
- Insiders 3.32%
- Institutions 96.68%
- Public & others 0.00%
- Shares outstanding 45.5M
- Free float 44.9M
Top funds holding HAE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 1.64M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.45M | 3.18% | +0.29% | Sep 2026 |
| Neuberger Genesis Inv | 1.18M | 2.59% | -20.94% | Sep 2026 |
| iShares Russell 2000 ETF | 1.17M | 2.57% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.02M | 2.25% | -2.00% | Sep 2026 |
| Ariel Fund Investor | 574K | 1.26% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 516K | 1.13% | +0.15% | Aug 2026 |
| T. Rowe Price Small-Cap Value | 426K | 0.93% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 409K | 0.90% | -0.38% | Oct 2026 |
| Neuberger Intrinsic Value I | 364K | 0.80% | 0.00% | Sep 2026 |
| Touchstone Small Company A | 342K | 0.75% | -44.42% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 336K | 0.74% | -1.01% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 333K | 0.73% | +0.37% | Sep 2026 |
| Franklin Small Cap Growth Adv | 310K | 0.68% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 301K | 0.66% | -2.59% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 289K | 0.63% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 285K | 0.63% | -4.72% | Sep 2026 |
| T. Rowe Price New Horizons | 278K | 0.61% | 0.00% | Sep 2026 |
| T. Rowe Price US Smlr Coms Eq A | 269K | 0.59% | -15.50% | Sep 2026 |
| Vanguard Russell 2000 ETF | 268K | 0.59% | -1.09% | Sep 2026 |
Top institutions holding HAE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.91M | 12.98% | +5.15% | Jun 2026 |
| Neuberger Berman Group LLC | 4.18M | 9.18% | +17.37% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.55M | 5.59% | -0.50% | Jun 2026 |
| AQR Capital Management LLC | 2.27M | 4.98% | -32.48% | Jun 2026 |
| Ariel Investments, LLC | 2.06M | 4.53% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.06M | 4.52% | -1.47% | Jun 2026 |
| State Street Corp | 1.82M | 3.99% | +2.55% | Jun 2026 |
| Citadel Advisors Llc | 1.51M | 3.32% | +484.97% | Jun 2026 |
| Geode Capital Management, LLC | 1.29M | 2.83% | +5.60% | Jun 2026 |
| River Road Asset Management, LLC | 1.29M | 2.82% | -3.19% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.28M | 2.81% | -19.27% | Sep 2026 |
| Arrowstreet Capital Limited Partnership | 1.16M | 2.54% | -16.46% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.10M | 2.42% | +84.44% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.05M | 2.30% | +9.78% | Jun 2026 |
| UBS Group AG | 983K | 2.16% | +86.74% | Jun 2026 |
| Royal Bank of Canada | 780K | 1.71% | -9.06% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 765K | 1.68% | -14.05% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 637K | 1.40% | +51.52% | Jun 2026 |
| Deutsche Bank AG | 632K | 1.39% | +76.01% | Jun 2026 |
| Northern Trust Corp | 632K | 1.39% | +9.02% | Jun 2026 |
Haemonetics Corporation company profile
- Company name
- Haemonetics Corporation
- Ticker
- HAE.US
- Exchange
- USA Stocks
- Listed since
- May 9, 1991
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,009
- Fiscal year end
- March
- Address
- 125 Summer Street, Boston, MA, United States, 02110
- Phone
- 781 848 7100
- Website
- haemonetics.com
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation management
10- Mr. Christopher A. SimonCEO, President & Director · born 1964
- Mr. James C. D'Arecca CPACFO, Executive VP & Financial Officer · born 1971
- Mr. Frank W. Chan Ph.D.Executive VP & COO · born 1970
- Ms. Michelle L. Basil Esq., J.D.Executive VP, General Counsel & Secretary · born 1973
- Mr. Roy GalvinExecutive VP & Chief Commercial Officer · born 1970
- Ms. Farris Maryanne E. MaunsellVP, Chief Accounting Officer & Principal Accounting Officer · born 1976
- Ms. Olga GuyetteVP of IR & Treasury
- Mr. Josh GitelsonSenior Director of Global Communications
- Mr. Rajeev VarmaSenior Vice President of Strategy & Corporate Development
- Ms. Laurie A. MillerSenior VP & Chief Human Resources Officer · born 1974